Chengdu Zenitar Biomedical Technology Co., Ltd
Clinical trials sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- A single-center, non-randomized, open-label, single-dose mass balance study of [¹⁴C]Purinostat mesylate for injection in healthy participants Results expected Oct 2026 (estimated)
- New hope for Hard-to-Treat lymphoma: experimental drug shows promise Results expected Dec 2026 (estimated)
- Can common drugs change how a new cancer medicine works? Results expected Dec 2026 (estimated)
- Can a new experimental pill be safely given to people? Results expected Jul 2027 (estimated)
- New pill could help control blood disorder when standard drugs fail Results expected Jul 2027 (estimated)
-
Can a new pill shrink the spleen in myelofibrosis?
Disease control OngoingThis trial is testing an experimental drug called flonoltinib in people with intermediate to high-risk myelofibrosis, a type of bone marrow cancer that often causes an enlarged spleen. Participants will be randomly assigned to receive either a low or high dose of flonoltinib, or …
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug shows promise for tough lymphomas in early trial
Disease control OngoingThis Phase 2 trial tests a new drug called purinostat mesylate in 50 people with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. The drug is given by IV four times per 21-day cycle for up to 96 weeks. The main goal is to see if it can shrink tumors…
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for Hard-to-Treat lymphoma: experimental drug shows promise
Disease control OngoingThis study tests a new drug called purinostat mesylate in 74 adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer that has come back or not responded to treatment). The goal is to see if the drug can shrink tumors and control the disease, while…
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC